

ARCADIA-CSI

Cognition and Silent Infarcts







- ARCADIA-CSI patients and their families
- Study site coordinators and investigators
- Project managers: Stephanie Kemp, Tashia Harris, Laura Benken, Kalli Beasley
- Imaging Core at MD Anderson
- StrokeNet NCC and NDMC teams
- ARCADIA study team
- NIH/NINDS

Stanford University Coordinating Center



Maarten Lansberg



Stephanie Kemp

MD Anderson **Imaging Core**



Max Wintermark

MUSC - StrokeNet DCC



Christy Cassarly

Faria Khattak



Angela Pauls

Univ of Cincinnati - StrokeNet NCC



Joe Broderick



Jamey Frasure



Kali Beasley



Tashia Harris



Laura Benken

UAB **Cognitive and Stats Core**





Ron Lazar

George Howard





Mike Brewer

Yale University Enrollment



U. Washington ARCADIA Trial




David Tirschwell



Overview



Overview




Inclusion and Exclusion

Inclusion Criteria

- Randomized in ARCADIA
- Able to undergo MRI
- Able to provide informed consent

Exclusion Criteria

- ARCADIA study drug permanently discontinued
- Diagnosis of dementia
- Active illicit drug use
- Admission for depression
- <8 years of education</p>
- TBI with >30 min loc





ARCADIA-MRI

Background


Covert infarcts are common

- Prevalence 30-50%
- Incidence up to 19% annually after TIA
- Covert infarcts are important
 - Associated with increased risk of cognitive impairment and dementia
 - Associated with increased risk of clinical stroke

• Two secondary stroke prevention studies have focused on covert infarcts


- NAVIGATE-ESUS and PACIFIC-Stroke
- Annual rate of covert infarcts 10-22%

Timing of MRI Scans



MRI Interpretation


- Follow-up scans rated for the presence of new silent infarcts
- Lacunar infarcts defined as round or ovoid subcortical lesions <15 mm in diameter



Statistical Analysis

 The relative risk of the incidence of one or more new non-lacunar covert infarcts during follow-up was estimated using Poisson regression with adjustment for follow-up time and inverse probability weighting to account for missing follow-up MRI studies





Baseline Characteristics of Enrolled Patients

	Included (n=174)	Excluded (n=136)
Age, Mean (SD)	66.3 (10.6)	67.2 (9.7)
Female, no. (%)	83 (47.7)	72 (52.9)
Black, no. (%)	33 (19.0)	30 (22.1)
Hypertensive, no. (%)	128 (73.6)	104 (76.5)
Diabetic, no. (%)	44 (25.3)	43 (31.6)
Prior stroke or TIA (before index), no. (%)	36 (20.7)	27 (19.9)
Modified Rankin Scale, Median (IQR)	1 (0-2)	1 (0-2)
NIHSS, Median (IQR)	0 (0-2)	1 (0-3)
Fazekas score, Median (IQR)	2 (1-3)	2 (1-3)

Baseline Characteristics of Included Patients

	Apixaban (n=79)	Aspirin (n=95)
Age, Mean (SD)	66.3 (10.2)	66.3 (11.0)
Female, no. (%)	37 (46.8)	46 (48.4)
Black, no. (%)	13 (16.5)	20 (21.1)
Hypertensive, no. (%)	57 (72.2)	71 (74.7)
Diabetic, no. (%)	16 (20.3)	28 (29.5)
Prior stroke or TIA (before index), no. (%)	12 (15.2)	24 (25.3)
Modified Rankin Scale, Median (IQR)	1 (0-2)	1 (0-2)
NIHSS, Median (IQR)	0 (0-2)	1 (0-2)
Fazekas score, Median (IQR)	2 (1-3)	2 (1-3)

Study Characteristics of Included Patients

	Apixaban (n=79)	Aspirin (n=95)	P-value
Time from ARCADIA randomization to ARCADIA-CSI consent, median (IQR), days	179 (48, 364)	93 (37, 362)	0.47
Time from baseline to follow-up MRI, median (IQR), days	800 (479-1311)	822 (487-1238)	0.65
Discontinued study drug prematurely, no. (%)*	14 (17.7)	13 (13.7)	0.46


^{*}A subject was considered to have "Discontinued study drug prematurely" if they discontinued study drug permanently before the date that sites were notified of trial end (12/21/22) and more than seven days before their censor date in the parent trial.

Primary Outcome	Apixaban (n=79)	Aspirin (n=95)	RR (95% CI)	P-value
≥1 non-lacunar covert infarct				


Primary Outcome		Aspirin (n=95)	RR (95% CI)	P-value
≥1 non-lacunar covert infarct	4 (5%)			

Primary Outcome	Apixaban (n=79)	Aspirin (n=95)	RR (95% CI)	P-value
≥1 non-lacunar covert infarct	4 (5%)	17 (18%)		

Primary Outcome		Aspirin (n=95)	RR (95% CI)	P-value
≥1 non-lacunar covert infarct	4 (5%)	17 (18%)	0.29 (0.10 – 0.83)	0.02







Secondary Outcome

Composite of ≥1 non-lacunar covert infarct or a non-lacunar clinical stroke

Outcome	Apixaban (n=79)	Aspirin (n=95)	RR (95% CI)	P-value
≥1 non-lacunar covert infarct	4 (5%)	17 (18%)	0.29 (0.10 – 0.83)	0.02
≥1 non-lacunar covert infarct or a non-lacunar clinical stroke	7 (9%)	25 (26%)	0.36 (0.17 – 0.79)	0.01

Additional Outcomes

Outcome	Apixaban (n=79)	Aspirin (n=95)	RR (95% CI)	P-value
≥1 non-lacunar covert infarct	4 (5%)	17 (18%)	0.29 (0.10 – 0.83)	0.02
≥1 non-lacunar covert infarct or a non-lacunar clinical stroke	7 (9%)	25 (26%)	0.36 (0.17 – 0.79)	0.01
Additional Outcomes				
Non-lacunar clinical stroke	3 (4%)	8 (8%)	0.52 (0.15 – 1.77)	0.30

Additional Outcomes

Outcome	Apixaban (n=79)	Aspirin (n=95)	RR (95% CI)	P-value
≥1 non-lacunar covert infarct	4 (5%)	17 (18%)	0.29 (0.10 – 0.83)	0.02
≥1 non-lacunar covert infarct or a non-lacunar clinical stroke	7 (9%)	25 (26%)	0.36 (0.17 – 0.79)	0.01
Additional Outcomes				
Non-lacunar clinical stroke	3 (4%)	8 (8%)	0.52 (0.15 – 1.77)	0.30
≥1 lacunar covert infarct	8 (10%)	12 (13%)	0.80 (0.34 – 1.86)	0.60

Additional Outcomes

Outcome	Apixaban (n=79)	Aspirin (n=95)	RR (95% CI)	P-value
≥1 non-lacunar covert infarct	4 (5%)	17 (18%)	0.29 (0.10 - 0.83)	0.02
≥1 non-lacunar covert infarct or a non-lacunar clinical stroke	7 (9%)	25 (26%)	0.36 (0.17 – 0.79)	0.01
Additional Outcomes				
Non-lacunar clinical stroke	3 (4%)	8 (8%)	0.52 (0.15 – 1.77)	0.30
≥1 lacunar covert infarct	8 (10%)	12 (13%)	0.80 (0.34 – 1.86)	0.60
≥1 lacunar or non-lacunar covert infarct	12 (15%)	25 (26%)	0.57 (0.31 – 1.07)	0.08

- High percentage (44%) of enrolled patients did not return for their follow-up MRI
- Patients included in the ARCADIA-MRI analysis were less likely to discontinue study drug prematurely (15.5%) than patients who were screened but not enrolled (50.8%)

Conclusion

Among patients with a cryptogenic stroke and atrial cardiopathy, apixaban as compared to aspirin:

- prevents non-lacunar covert infarcts
- does not prevent lacunar covert infarcts



ARCADIA-Cognition

Cognition and Covert Infarction


Vermeer SE et al. Prevalence and risk factors of silent brain infarcts in the populationbased Rotterdam Scan Study. Stroke. Jan 2002;33(1):21-5.


Vermeer SE, Longstreth WT, Jr., Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. Jul 2007;6(7):611-9. doi:10.1016/S1474-4422(07)70170-9

latrogenic Etiology: CABG (Tachibana, 2021), TAVR (Lazar, 2018), AF Ablation (Hahne, 2016)


Specific Aim 2: Determine the effect of apixaban (vs aspirin) on the longitudinal <u>rate of change (i.e., slope)</u> of global cognitive function after stroke (primary clinical outcome).

ARCADIA-CSI Cognitive Test Battery (Administered via Phone by the UAB Survey					
Test	Domain				
CERAD Word List Learning	Learning				
Digit Span	Attention				
CERAD Delayed Recall	Memory				
Animal Fluency	Executive Function				
Letter Fluency					
Oral Trail Making*					





Baseline Characteristics/Follow-up Visits	Apixaban (n = 128)	Aspirin (n = 121)
Age at time of CSI consent, Mean (SD)	66.7 (10.3)	66.8 (10.6)
Female, no. (%)	64 (50.0)	65 (53.7)
Black, no. (%)	20 (15.6)	28 (23.1)
Hypertensive, no. (%)	96 (75.0)	89 (73.6)
Diabetic, no. (%)	31 (24.2)	35 (28.9)
Education n (%)		
<high school<="" td=""><td>3 (2.3)</td><td>5 (4.1)</td></high>	3 (2.3)	5 (4.1)
High School Graduate or GED	34 (26.6)	26 (21.5)
Partial College or Specialized Training	40 (31.3)	30 (24.8)
College Graduate	26 (20.3)	31 (25.6)
Graduate Professional Degree	25 (19.5)	29 (24.0)
Cognitive Exams Completed (%)		
Baseline	127 (99.2)	120 (99.2)
Follow-Up Visit 1	95 (74.2)	93 (76.9)
Follow-Up Visit 2	53 (41.4)	55 (45.5)
Follow-Up Visit 3	18 (14.1)	20 (16.5)
Follow-Up Visit 4		1 (1.0)



	Apixaban (n=128)	Aspirin (n=121)
ARCADIA Index stroke to first Cognitive exam (days), median (IQR)	264 (IQR: 141, 539)	249 (IQR: 138, 504)
First cognitive exam to last cognitive Exam (days), median (IQR)	374 (IQR: 0, 738)	413 (IQR: 225, 734)

Estimated Annual Change				
Aspirin	Apixaban			
0.084	0.107			
(0.018 - 0.149)	(0.041-0.174)			
P = 0.62				

Estimated Annual Change by Cognitive Test

	Aspirin	Apixaban	P-value
Verbal	0.089	0.109	0.69
Fluency	(0.022 – 0.156)	(0.040 – 0.177)	
Digit Span	0.069 (-0.008 – 0.147)	0.046 (-0.033 – 0.124)	0.67
Animal	0.026	0.109	0.14
Naming	(-0.053 – 0.104)	(0.030 – 0.189)	
Word List	0.096	0.094	0.97
Learning	(0.008 – 0.185)	(0.005 – 0.183)	
Word List	0.057	0.060	0.97
Recall	(-0.038 – 0.153)	(-0.036 – 0.156)	

Factor Affecting Cognitive Effects

- Duration of Follow-Up
- Number of Covert Infarcts
- Volume of Covert Infarcts
- Location of Covert Infarcts
- Time since index stroke

